Q4 2022 Results

Company overview Financial review 2023 priorities Appendix PluvictoⓇ manufacturing capacity is set to significantly expand in 2023 with bringing Millburn and Indianapolis on-line Expected coverage by end 2023 Manufacturing site1: Ivrea Millburn Indianapolis Zaragoza Commercial US, EU, ROW² Canada, US3 US3 Clinical EU, ROW Canada, US, EU EU, ROW² Targeting capacity of at least 250k doses annually for 2024+ 1. Additional manufacturing sites in Asia under evaluation. 2. Dependent on regulatory approval. 3. Expected in H2 2023. 32 Investor Relations | Q4 2022 Results GROWTH P PLUVICTO NOVARTIS | Reimagining Medicine

View entire presentation